ophthalmology
Ophthalmic Drugs Conference
Nikisha Galoria
AI, eyecare, gene therapy, myopia, ophthalmology
0 Comment
Ophthalmic Drugs Conference
Digital/ News/ News/ News/ Patients
Could an eye test spot people at risk of heart attacks?
Phil Taylor
cardiovascular disease, diagnosis, digital health, ophthalmology
0 Comment
2nd Integrin-Targeted Drug Development Summit
Erin Thomas
autoimmune, integrin, ophthalmology, Rare diseases
0 Comment
Oxurion craters as failed trial cuts its pipeline down to one
Phil Taylor
diabetic macular oedema, ophthalmology, Oxurion
0 Comment
Longer-term data raise prospects for Apellis’ pegcetacoplan
Phil Taylor
Apellis Pharma, blindness, complement therapeutics, Empaveli, geographic atrophy, ophthalmology, pegcetacoplan
0 Comment
Oxurion reports stronger data for diabetic eye disease drug
Phil Taylor
Bayer, diabetic macular oedema, Eylea, ophthalmology, Oxurion, Regeneron
0 Comment
Roche grabs FDA okay for would-be blockbuster eye drug faricimab
Phil Taylor
Bayer, DME, Eylea, ophthalmology, Regeneron, regulatory approval, Roche, Susvimo, Vabysmo, wet AMD
0 Comment
News/ News/ Sales and Marketing
AbbVie prices first presbyopia drug Vuity at $80 per month
Phil Taylor
AbbVie, Allergan, ophthalmology, presbyopia, pricing, Vuity
0 Comment